Cipla, Glenmark shares hit 52-week high over launch of COVID-19 drugs
Cipla's shares on Monday surged 9.2% to hit a new 52-week high of ₹696 on BSE. This comes after it was allowed to manufacture and supply antiviral drug remdesivir for treatment of suspected or confirmed
Cipla’s shares on Monday surged 9.2% to hit a new 52-week high of ₹696 on BSE. This comes after it was allowed to manufacture and supply antiviral drug remdesivir for treatment of suspected or confirmed cases of COVID-19. Shares of Glenmark Pharmaceuticals also surged 40% to a 52-week high of ₹572.7 after it launched antiviral drug favipiravir for COVID-19 treatment.
